2012 Molecular Biology Therapies 
Drug Target Review
NOVEMBER 27, 2023
By directly interfering with the eIF4F complex, eFFECTOR’s STRIs provide a promising avenue for disrupting the core mechanisms of cancer, offering the potential to improve patient outcomes and overcome the limitations of traditional cancer therapies. Dr Worland has served on the board of directors of Tracon Pharmaceuticals, Inc.,
Drug Target Review
AUGUST 29, 2024
What potential advantages does the CD5 modulation strategy offer over traditional CAR-T therapies? MR : Chimeric antigen receptor T-cell (CAR-T) therapy is very effective in treating patients with B-cell lymphoma, leukemia, and multiple myeloma, where we have six FDA-approved drugs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Drug Target Review
MAY 27, 2024
What role do ADCs play in Caris’ strategy for targeted cancer therapy, particularly in terms of patient-specific treatment plans? At a base-layer, Caris’ comprehensive molecular profiling that we perform for patients today can identify predictive biomarkers for current FDA-approved ADCs.
Broad Institute
JANUARY 30, 2024
He majored in biological chemistry at the University of Chicago and during his junior year, he had a fortuitous meeting with his academic advisor about finding a student research position that would let him dive more deeply into the molecular details of biological systems. A combined MD/PhD program offered both opportunities.
Codon
DECEMBER 17, 2023
Molecular biology, as the field came to be called 3 , pushed biology from an object of study, driven forward by gentleman scientists and precocious country clergymen, into a tool with which to solve urgent problems. CRISPR gene-editing was invented in 2012 and applied to human embryos soon after.
Codon
JUNE 26, 2023
Since the last Codon Digest, I’ve published: Reasons to Be Grateful for Biotechnology (with Avadhoot Jadhav) AAV Foundations (Part I) An overview of AAV-based gene therapies, how they get made, and where they go wrong. Nevertheless, phage therapy did have a stint in the U.S. I’ll post an update soon. coli in mice.
Codon
JUNE 26, 2023
Since the last Codon Digest, I’ve published: Reasons to Be Grateful for Biotechnology (with Avadhoot Jadhav) AAV Foundations (Part I) An overview of AAV-based gene therapies, how they get made, and where they go wrong. Nevertheless, phage therapy did have a stint in the U.S. I’ll post an update soon. coli in mice.
Expert insights. Personalized for you.
87 
Let's personalize your content